February 05, 2026 a 05:01 pm
ABT: Analysts Ratings - Abbott Laboratories
Abbott Laboratories, a major player in the healthcare sector, has shown consistent innovation across its various segments. The company's stock is influenced by its robust product portfolio, making it a focal point for investor interest. Recent analyst ratings suggest a stable outlook with room for potential growth, underpinned by strong market demand for healthcare solutions.
Historical Stock Grades
Analyzing the data from February 2026, the latest analyst ratings indicate a positive sentiment towards Abbott Laboratories.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 15 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the months, ratings for Abbott Laboratories reveal several trends.
- The total count of strong buy and buy ratings remains consistently high, signaling confidence in the stock.
- A slight fluctuation in the hold ratings indicates some analysts are exercising caution.
- No recent sell or strong sell ratings illustrate a lack of negative sentiment in the near-term outlook.
Percentage Trends
In analyzing the recent data, there are slight shifts in analyst sentiment.
- Strong Buy ratings have decreased from a historical high, now holding at 6 counts.
- The Buy ratings remain dominant with a steady 15 recommendations.
- Hold ratings show an oscillation, suggesting some market participants may wait for further developments.
Latest Analyst Recommendations
Reviewing the most recent analyst recommendations demonstrates consistent belief in Abbott's future prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-02 | Overweight | Overweight | Barclays |
| 2026-01-23 | Outperform | Outperform | Evercore ISI Group |
| 2026-01-23 | Outperform | Outperform | Bernstein |
| 2026-01-23 | Overweight | Overweight | Piper Sandler |
| 2026-01-23 | Buy | Buy | Citigroup |
Analyst Recommendations with Change of Opinion
Shifts in opinions are occasionally observed, as seen in historical data.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-18 | Buy | Hold | Jefferies |
| 2023-07-21 | Peer Perform | Underperform | Wolfe Research |
| 2023-07-20 | Peer Perform | Underperform | Wolfe Research |
| 2021-10-27 | Overweight | Neutral | Atlantic Equities |
| 2021-10-26 | Overweight | Neutral | Atlantic Equities |
Interpretation
The stable hold of Buy and Strong Buy ratings suggests a prevailing confidence in Abbott Laboratories' market potential. The absence of negative ratings emphasizes a positive outlook, whereas periodic shifts from neutral to positive ratings indicate evolving confidence in company strategies or market conditions. Current patterns underline a general continuity in analyst sentiment but the need for cautious optimism amid sector dynamics.
Conclusion
Abbott Laboratories continues to demonstrate strength in maintaining a favorable analyst rating profile, which is crucial given the competitive healthcare landscape. Opportunities in diagnostics and pharmaceuticals present robust growth potentials, while minor fluctuations in analyst sentiment indicate market vigilance. The risk is contingent on broader economic factors affecting healthcare demands. Overall, Abbott maintains a solid foundation for long-term growth.